Framework proposed for revaccination after BCMA-targeted autoimmune therapies

This paper proposes a practical revaccination framework for adult autoimmune disease patients treated with BCMA-targeting therapies, drawing on clinical evidence and oncology studies. The authors report that BCMA-targeting therapies reduce vaccine-specific antibody titres and total immunoglobulin levels, and note differences in immunosuppression magnitude and duration between autoimmune and malignancy populations. They propose a pragmatic approach using minimal serologic monitoring, while stating that future studies are needed to clarify optimal timing and need for revaccination.

Most relevant for: Adult patients with autoimmune diseases who have received or are being considered for BCMA-targeted immune-reset therapies, including CAR T-cell and bispecific T-cell engager approaches.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.